Literature DB >> 22458903

Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful?

Steven S Shen1, Luan D Truong, Marina Scarpelli, Antonio Lopez-Beltran.   

Abstract

CONTEXT: With the refinement of molecular and histologic classifications of renal neoplasms and the availability of more-effective molecular targeted therapy for specific renal neoplasms, immunohistochemical techniques will play an increasingly important role in the diagnosis of renal neoplasm. During the past few decades, many markers have been evaluated for their role in the diagnosis, prognosis, and prediction of treatment for renal neoplasms. The number of useful markers in our routine practice continues to increase. The challenge will be to choose among them and to decide in which situations immunohistochemistry will be truly useful.
OBJECTIVES: To review the diagnostic utility of molecular markers for renal neoplasms and common diagnostic scenarios that call for immunohistochemistry in routine practice. DATA SOURCES: This review is based on published literature and personal experience.
CONCLUSIONS: Some of the most important and useful markers for the diagnosis of renal neoplasm include cytokeratins, vimentin, PAX2, PAX8, RCC marker, CD10, E-cadherin, kidney-specific cadherin, parvalbumin, claudin-7, claudin-8, α-methylacyl coenzyme A racemase, CD117, TFE3, thrombomodulin, uroplakin III, p63, CD57, and carbonic anhydrase IX. Each marker has its diagnostic role in a specific diagnostic setting. The common diagnostic situations that call for immunohistochemical staining are differential diagnoses of renal versus nonrenal neoplasms, histologic subtyping of renal cell carcinoma, diagnosis of rare primary renal neoplasms, diagnosis of renal neoplasms in small core-biopsy specimens, diagnosis of possible metastatic renal carcinomas, and less frequently, molecular prognostication.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22458903     DOI: 10.5858/arpa.2011-0472-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  29 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

2.  [Personalized urooncology based on molecular uropathology: part 1: what is diagnostic routine?].

Authors:  C G Stöhr; R Stöhr; A Rogler; K Amann; R Knüchel-Clarke; A Hartmann
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

Review 3.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

4.  Metastatic renal cell carcinoma with undetectable renal mass presenting as lymphadenopathy.

Authors:  Mohamed Salah Fayaz; Aishah Ebrahim Al-Qaderi; Mustafa Shawki El-Sherify
Journal:  CEN Case Rep       Date:  2016-10-26

5.  PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Authors:  Meaghan L Barr; Lucia B Jilaveanu; Robert L Camp; Adebowale J Adeniran; Harriet M Kluger; Brian Shuch
Journal:  J Clin Pathol       Date:  2014-10-14       Impact factor: 3.411

6.  Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas.

Authors:  Yael Spector; Eddie Fridman; Shai Rosenwald; Sofia Zilber; Yajue Huang; Iris Barshack; Orit Zion; Heather Mitchell; Mats Sanden; Eti Meiri
Journal:  Mol Oncol       Date:  2013-03-26       Impact factor: 6.603

Review 7.  [The role of pathology in the diagnostics of CUP syndrome].

Authors:  A Stenzinger; M Kriegsmann; W Weichert
Journal:  Radiologe       Date:  2014-02       Impact factor: 0.635

8.  MicroRNAs as potential diagnostic biomarkers in renal cell carcinoma.

Authors:  Yongqing Gao; Hongmei Zhao; Ying Lu; Haiyi Li; Gaobo Yan
Journal:  Tumour Biol       Date:  2014-08-06

9.  Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.

Authors:  Tram Anh Tran; Hon Sing Leong; Andrea Pavia-Jimenez; Slavic Fedyshyn; Juan Yang; Blanka Kucejova; Sharanya Sivanand; Patrick Spence; Xian-Jin Xie; Samuel Peña-Llopis; Nicholas Power; James Brugarolas
Journal:  Mol Cell Biol       Date:  2016-06-15       Impact factor: 4.272

10.  Metastatic renal cell carcinoma without evidence of a primary renal tumour.

Authors:  R M Kumar; T Aziz; H Jamshaid; J Gill; A Kapoor
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.